JointHealth™ express   June 7, 2019

Good news for Quebec residents living with rheumatoid arthritis

The Institut national d’excellence en santé et en services sociaux has recently added sarilumab (Kevzara®) to their provincial formulary for the treatment of rheumatoid arthritis

Sarilumab is approved by Health Canada for the treatment of rheumatoid arthritis. Click here to view the detailed medication criteria in Quebec’s provincial formulary.

Sarilumab is an interleukin-6 receptor antagonist and has received a Health Canada Notice of Compliance for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).